Předmět: |
|
Zdroj: |
Gastroenterology Week; 11/5/2024, p1750-1750, 1p |
Abstrakt: |
Researchers from Chungbuk National University in South Korea have conducted a study on the effects of inhibiting the enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) on metabolic dysfunction-associated steatotic liver disease (MASLD) and fibrosis. The study found that the inhibitor INU-101 effectively reduced cortisol-induced lipid accumulation, oxidative stress, and liver damage in mice fed a fast-food diet. The research suggests that INU-101 could be a potential therapeutic candidate for treating MASLD and fibrosis by targeting the processes involving 11b-HSD1 and cortisol regulation in the liver. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|